Researches, develops, manufactures, and markets diagnostic and research products. Offers products based on genetic engineering, biotechnology, and molecular biology. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
An average decline of 20% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
An investor who bought at the very peak is down 92% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The company sells $31.9M a year; the problem isn’t sales — it’s costs running above that number.
Over the last 12 months, company executives reported 5 buys and 1 sell. Management buying with its own money is usually read as a good sign.
It pays out $0.10 per share each year — regular cash for whoever holds the stock.
A loss of $26.1M against $31.9M in annual sales.
The stock sits at $0.31. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At the current pace of spending, the cash lasts about 2 years. After that, the company needs to find new money.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.